Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
thalidomide analogue being developed to treatinflammatory diseases .
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word apremilast.
Examples
-
Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis
THE MEDICAL NEWS 2010
-
This work is highlighted by the initiation this year of four pivotal studies investigating apremilast in psoriasis and psoriatic arthritis.
Celgene Q3 2010 Earnings Call Transcript -- Seeking Alpha 2010
-
Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis
THE MEDICAL NEWS Editors 2010
-
We are also conducting late-stage trials for apremilast, pomalidomide, Amrubicin, VIDAZA and ISTODAX.
Celgene Q3 2010 Earnings Call Transcript -- Seeking Alpha 2010
-
We now have 25 pivotal trials investigating REVLIMID, VIDAZA, ISTODAX, pomalidomide, apremilast and now ABRAXANE across a number of diseases with high unmet medical needs.
Celgene Q3 2010 Earnings Call Transcript -- Seeking Alpha 2010
-
By 2015, our goal is to achieve a number of approvals for apremilast while continuing to accelerate the development of this pipeline.
Celgene Q3 2010 Earnings Call Transcript -- Seeking Alpha 2010
-
The company is looking to boost its pipeline further and currently has several late-stage candidates including apremilast, pomalidomide, Amrubicin and Istodax, which are targeting diseases like cancer and psoriasis among others.
-
During the last two quarters, we have initiated four out of our six pivotal studies in psoriasis and psoriatic arthritis with apremilast.
Celgene Q3 2010 Earnings Call Transcript -- Seeking Alpha 2010
-
Key regulatory trials studying REVLIMID, pomalidomide, apremilast and our proprietary cellular therapy, PDA-001, progressed meaningfully in the quarter.
Celgene Q3 2010 Earnings Call Transcript -- Seeking Alpha 2010
-
These R&D expenditures continue to support ongoing clinical progress in multiple proprietary development programs for REVLIMID, pomalidomide and other IMiDs compounds; VIDAZA; amrubicin, our lead compound for small cell lung cancer; apremilast and our oral anti-inflammatory compounds; as well as our kinase inhibitor programs; our Activin inhibitor program and placenta-derived stem cell programs.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.